您当前的位置:首页 > 财经 > 财富商机 > 德琪医药塞利尼索12项研究摘要入选202....

德琪医药塞利尼索12项研究摘要入选2021 EHA年会

2021-06-02 11:24:43 浏览: 2 作者: 小家碧玉
摘要:投资研报【硬核研报】下一只隆基股份?“颗粒硅”推动硅料成本骤降70%,光伏硅片有望“三分天下”!光伏新秀已拿下305亿元超大订单,价值却被严重低估尾盘10分钟涨停!总龙头轰出7板!机构爆买1只次新股打出6板1年10倍:次高端白酒迎“牛市”!未来5年2-3个百亿大单品在这些公司中跑出(受益股)震惊:嘉实基金洪流、姚志鹏、

投资研报

【硬核研报】下一只隆基股份?“颗粒硅”推动硅料成本骤降70%,光伏硅片有望“三分天下”!光伏新秀已拿下305亿元超大订单,价值却被严重低估

尾盘10分钟涨停!总龙头轰出7板!机构爆买1只次新股打出6板

1年10倍:次高端白酒迎“牛市”!未来5年2-3个百亿大单品在这些公司中跑出(受益股)

震惊:嘉实基金洪流、姚志鹏、归凯等调研1股!萧楠、丘栋荣等调研股同步曝光(名单)

致力于研发和商业化创新肿瘤疗法的领先生物制药公司--德琪医药有限公司(简称“德琪医药”,香港联交所股票代码:6996.HK)今日宣布,同类首款选择性核输出抑制剂——塞利尼索(selinexor)12项研究及成果入选欧洲血液学协会(EHA)年会。此届 EHA 会议将于6月9日至6月17日在线上召开。

线上摘要

Phase 2 MARCH study of oral ATG-010 plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously exposed to an immunomodulatory agent and a proteasome inhibitor.

摘要编号:PB1670

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

摘要编号:S188

Selinexor containing regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies.

摘要编号:EP1002

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed/refractory multiple myeloma (MM).

摘要编号:EP1008

Ciltacabtagene Autoleucel versus selinexor + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) treated with ≥ 3 lines of prior therapy:A matching adjusted indirect comparison.

摘要编号:EP1049

Cost effectiveness comparison of belantamab mafodotin and selinexor in relapsed refractory multiple myeloma.

摘要编号:EP1173

Lymphocyte count effect on efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL):A post-hoc analysis from phase 2B SADAL study.

摘要编号:EP530

Genomic correlates of respones to selinexor in multiple myeloma from the BOSTON study reveal a predictive signature.

摘要编号:EP936

Effects of selinexor on previously treated multiple myeloma (MM) with RAS-mutations.

摘要编号:EP966

Efficacy and safety of selinexor, bortezomib, and dexamethasone based on refractory status to lenalidomide in patients with previously treated multiple myeloma:A post-hoc analysis of the BOSTON study.

摘要编号:EP976

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

摘要编号:EP924

关于德琪医药

德琪医药有限公司(简称“德琪医药”,香港联交所股票代码:6996.HK)是一家以研发为驱动的生物制药领先企业,致力于为亚太乃至全球患者提供最领先的疗法,治疗肿瘤及其他危及生命的疾病。自2017年正式运营以来,德琪医药通过合作引进和自主研发,建立了一条从临床前到临床阶段不断延展的丰富产品管线。目前,德琪医药已在多个亚太市场获得15个临床批件(IND),并递交了5个新药上市申请(NDA)。德琪医药将以“医者无疆,创新永续”为愿景,专注于同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化,解决亟待满足的临床需求。

《电鳗快报》

牛市来了?如何快速上车,金牌投顾服务免费送>>德琪医药塞利尼索12项研究摘要入选2021 EHA年会海量资讯、精准解读,尽在本站财经APP

热门推荐
返回顶部